Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastoma--Report of two exceptional cases.
The morphologic pattern of contrast enhancement in magnetic resonance imaging (MRI) of glioblastoma patients could be non specific and metabolic investigations can be useful for the differentiation of tumorous and non tumorous enhancement. Following initial therapy secondary tissue changes can occur and non specific non tumorous enhancement phenomena have been observed after local immuno- and gene therapy strategies. Magnetic resonance spectroscopic imaging (MRSI) has the potential to give more specific information on the metabolism of the suspective tissue and to differentiate enhancing phenomena. We demonstrate two cases of patients suffering from a glioblastoma with simultaneous MRI and MRSI follow-up after multimodal treatment with surgery, radiation, intralesional immunotherapy (IL-4 toxin) and ongoing chemotherapy. MRI demonstrated extensive and increasing enhancement. This was highly suspicious of rapid progressive local tumor recurrency in both patients. Simultaneously obtained MRSI did not show the expected result of extensive and increasing choline concentration within these enhancing areas. This indicated that the enhancement did most likely not reflect vital tumor tissue. Chemotherapy treatment was continued and further MRI follow up revealed nearly complete regression of all enhancement. In pretreated glioblastoma metabolic data of MRSI seem to be potentially helpful to differentiate tumorous and non tumorous enhancement phenomena after local immunotherapy, which might be useful for further treatment decisions.
Floeth
F W
FW
Neurochirurgische Klinik der Heinrich-Heine-Universität Düsseldorf, Germany. floethf@uni-duesseldorf.de
Wittsack
H J
HJ
Engelbrecht
V
V
Weber
F
F
D000328:Adult; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid / Q000473:pathology* / Q000628:therapy*; D002794:Choline / Q000134:cerebrospinal fluid; D017809:Fatal Outcome; D005260:Female; D005909:Glioblastoma / Q000134:cerebrospinal fluid / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007167:Immunotherapy / Q000379:methods*; D000922:Immunotoxins / Q000008:administration & dosage / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008845:Microinjections; D012008:Recurrence
D000922:Immunotoxins; D002794:Choline